Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

NASDAQ:GOSS - Nasdaq - US38341P1021 - Common Stock - Currency: USD

0.8764  -0.08 (-8.55%)

After market: 0.9062 +0.03 (+3.4%)

Fundamental Rating

2

Overall GOSS gets a fundamental rating of 2 out of 10. We evaluated GOSS against 566 industry peers in the Biotechnology industry. Both the profitability and financial health of GOSS have multiple concerns. While showing a medium growth rate, GOSS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GOSS has reported negative net income.
GOSS had a negative operating cash flow in the past year.
In the past 5 years GOSS always reported negative net income.
GOSS had a negative operating cash flow in each of the past 5 years.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -17.93%, GOSS belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
GOSS has a Return On Equity of -191.67%. This is in the lower half of the industry: GOSS underperforms 67.84% of its industry peers.
Industry RankSector Rank
ROA -17.93%
ROE -191.67%
ROIC N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

GOSS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

3

2. Health

2.1 Basic Checks

GOSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GOSS has been increased compared to 1 year ago.
The number of shares outstanding for GOSS has been increased compared to 5 years ago.
Compared to 1 year ago, GOSS has an improved debt to assets ratio.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GOSS has an Altman-Z score of -4.47. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
GOSS has a Altman-Z score (-4.47) which is in line with its industry peers.
GOSS has a Debt/Equity ratio of 6.70. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of GOSS (6.70) is worse than 84.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.7
Debt/FCF N/A
Altman-Z -4.47
ROIC/WACCN/A
WACC9.29%
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.88 indicates that GOSS has no problem at all paying its short term obligations.
GOSS has a Current ratio of 6.88. This is in the better half of the industry: GOSS outperforms 68.20% of its industry peers.
A Quick Ratio of 6.88 indicates that GOSS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.88, GOSS is in the better half of the industry, outperforming 68.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.88
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.29% over the past year.
EPS 1Y (TTM)81.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GOSS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.40% on average per year.
The Revenue is expected to grow by 25.82% on average over the next years. This is a very strong growth
EPS Next Y-173.14%
EPS Next 2Y-34.35%
EPS Next 3Y8.81%
EPS Next 5Y26.4%
Revenue Next Year-80.63%
Revenue Next 2Y-27.38%
Revenue Next 3Y6.02%
Revenue Next 5Y25.82%

3.3 Evolution

GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GOSS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GOSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.35%
EPS Next 3Y8.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOSS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (4/28/2025, 8:13:13 PM)

After market: 0.9062 +0.03 (+3.4%)

0.8764

-0.08 (-8.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners76.64%
Inst Owner Change-0.01%
Ins Owners0.69%
Ins Owner Change0%
Market Cap199.14M
Analysts82.67
Price Target6.33 (622.27%)
Short Float %4.17%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.31%
Min EPS beat(2)7.13%
Max EPS beat(2)13.49%
EPS beat(4)3
Avg EPS beat(4)4.08%
Min EPS beat(4)-5.81%
Max EPS beat(4)13.49%
EPS beat(8)7
Avg EPS beat(8)6.28%
EPS beat(12)9
Avg EPS beat(12)4.68%
EPS beat(16)11
Avg EPS beat(16)3.34%
Revenue beat(2)2
Avg Revenue beat(2)27.62%
Min Revenue beat(2)20.7%
Max Revenue beat(2)34.54%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.61%
PT rev (3m)-18.39%
EPS NQ rev (1m)1.51%
EPS NQ rev (3m)0.46%
EPS NY rev (1m)1.94%
EPS NY rev (3m)2.01%
Revenue NQ rev (1m)-4.18%
Revenue NQ rev (3m)14.27%
Revenue NY rev (1m)2.88%
Revenue NY rev (3m)2.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.74
P/FCF N/A
P/OCF N/A
P/B 6.75
P/tB 6.75
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.5
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.93%
ROE -191.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 6.7
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.88
Altman-Z -4.47
F-Score6
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)7.47%
Cap/Depr(5y)43.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-173.14%
EPS Next 2Y-34.35%
EPS Next 3Y8.81%
EPS Next 5Y26.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-80.63%
Revenue Next 2Y-27.38%
Revenue Next 3Y6.02%
Revenue Next 5Y25.82%
EBIT growth 1Y65.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-149.74%
EBIT Next 3Y33.89%
EBIT Next 5Y34.99%
FCF growth 1Y97.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y97.82%
OCF growth 3YN/A
OCF growth 5YN/A